Common treatment‐related adverse events of any grade included peripheral neuropathy (63.3%), anemia (95.0%), thrombocytopenia (65.0%), neutropenia (63.3%), increased aspartate aminotransferase (AST) (63.3%), and increased alanine aminotransferase (ALT) (50.0%). The gene discussed is GPT; the disease is peripheral neuropathy.